Companies Dominating the Estrogen Receptor Agonist Landscape
- AstraZeneca
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- ESTRIGENIX
- Karo Healthcare AB
- Merck KGaA
- Vivesto AB
- Oncternal Therapeutics
- Pfizer Inc.
- Tocris Bioscience
- Tokyo Chemical Industry Co., Ltd
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of estrogen receptor agonist is evaluated at USD 5.21 billion.
The estrogen receptor agonist market size was valued at USD 4.63 billion in 2024 and is set to exceed USD 12 billion by 2037, registering over 7.6% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.
Asia Pacific industry is predicted to dominate majority revenue share by 2037, backed by growing geriatric population in this region.
The major players in the market are AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, Merck KGaA, Vivesto AB, Oncternal Therapeutics, Pfizer Inc., Tocris Bioscience, Tokyo Chemical Industry Co., Ltd
